Sildenafil citrate therapy for pulmonary arterial hypertension. - Wikidata - awgldk - TriplyDB

Sildenafil citrate therapy for pulmonary arterial hypertension.

Sildenafil citrate therapy for pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q34562650

about

Endothelin receptor antagonists for pulmonary arterial hypertension Endothelin receptor antagonists for pulmonary arterial hypertension Phosphodiesterase 5 inhibitors for pulmonary hypertension Inhaled treprostinil: a therapeutic review Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension The limits of oral therapy in pulmonary arterial hypertension management The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review The molecular targets of approved treatments for pulmonary arterial hypertension Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan Erectile dysfunction in heart failure patients: a critical reappraisal Drug treatment of pulmonary hypertension in children Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications Pulmonary vascular complications of liver disease The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction Structural insight into substrate specificity of phosphodiesterase 10 The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10 Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies Kinetic and Structural Studies of Phosphodiesterase-8A and Implication on the Inhibitor Selectivity † ‡Conformation Changes, N-terminal Involvement, and cGMP Signal Relay in the Phosphodiesterase-5 GAF Domain Structural Asymmetry of Phosphodiesterase-9, Potential Protonation of a Glutamic Acid, and Role of the Invariant Glutamine Structure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor Design Dual Specificity and Novel Structural Folding of Yeast Phosphodiesterase-1 for Hydrolysis of Second Messengers Cyclic Adenosine and Guanosine 3′,5′-Monophosphate Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation.Pulmonary arterial hypertension: a comparison between children and adults A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy Treatment-related biomarkers in pulmonary hypertension Recent strategies in treatment of pulmonary arterial hypertension, a review Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial Novel biomarkers for risk stratification in pulmonary arterial hypertension Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding Pulmonary Hypertension in Children.Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

P2860

Q24200714-D3FFB336-A77C-4CDB-8821-6BC06717D631 Q24240009-6D339FF3-C869-4FF4-A751-5CFB9343561C Q24245844-42E7207F-2505-4BCA-93BA-260D37442FF7 Q24601864-B3F879EC-FEA0-4E83-B6FB-B5F0787F019D Q24681558-2A6201DE-435B-4FC1-8B36-C457121C3C58 Q26747812-0D30DBC4-1674-49E7-8524-5B18F2D88AE8 Q26747940-190D6FA3-58EF-4CDB-95B3-A29BD902C5C1 Q26765931-ADDC57F0-73D2-4FB4-BD5C-369BA52C7F04 Q26771505-F10B8DD5-F630-4A87-8788-76ECE4A934F1 Q26773209-702781C6-7710-438C-9531-0674676B9E8E Q26785428-44DA3E00-ABDD-40E9-A36E-02B68434D63D Q26798308-EE2DAC92-5C9C-41EA-A5AA-8E94A952DB23 Q26851546-0B2EBB5B-35D0-4FD5-9B6A-61EC21FFD856 Q26853624-95BB9E5D-26F6-48FE-BAFD-A323DBCDA04D Q26996078-F9E8CA9A-14BC-42DE-8D80-C103C39CA001 Q26996772-204C0385-458C-40E2-8784-E9A6363C825C Q27021918-7B28179D-8E7F-4733-A292-00A398DB40EA Q27024279-97AB6035-8A82-43F5-8BAB-54EAA1673A5C Q27644254-46DBA8B6-71A5-4874-A67C-AD29CB63CEB6 Q27646209-FCB5AF9F-23AF-4A42-8157-F49017B8AE7C Q27648821-665D6B33-6703-403A-94EE-7D37002A211A Q27648887-E37701AE-9230-4493-813A-D5190A524410 Q27650091-AB26D962-5F08-442A-86B8-B5167D3F9F6A Q27652751-140DCDA2-29F3-4412-AA7C-8228EDBD10E1 Q27664639-05B64F47-D917-4850-BB70-7398C461336E Q27667496-D5C9C9CF-3E62-45BC-A683-C97AC8BF8D2E Q27673292-22654F9F-23C3-40A8-85B7-48263BA18D5C Q27684785-3905029D-616E-4654-A332-C380A4DBB830 Q27687091-276EB40E-6E41-40E6-96EF-AA3712B5A556 Q27687320-3D3A76A9-0E83-43CD-A68F-32952782ED0E Q28072562-ED816EA6-5A0C-4A19-B38B-5F35B89B8CD3 Q28081276-CE90F7B9-F76B-4FFF-A59B-FB57A34B2FA2 Q28084702-94A31F91-D176-4353-883C-AB4711D8A9D4 Q28085572-70601923-20C9-4474-A13F-A8369014F5DD Q28395387-5DEC6189-28BF-460D-84FE-76E7A8BA1066 Q28544798-F1B7154F-B218-497B-8935-91A92ED04D8E Q28596829-0F086873-ADB0-4FC7-94A8-DCEA1FCE5292 Q29248756-C021F353-7F9D-4105-B227-551C5BCCF23D Q30248871-E554D36A-3A49-4C0A-9B30-4A461260BB84 Q30251818-844B7E00-5993-4FA7-B1C4-5DB00840DA2C

P2860

Sildenafil citrate therapy for pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q34562650

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Sildenafil citrate therapy for pulmonary arterial hypertension.

@ast

Sildenafil citrate therapy for pulmonary arterial hypertension.

@en

Sildenafil citrate therapy for pulmonary arterial hypertension.

@nl

type

label

Sildenafil citrate therapy for pulmonary arterial hypertension.

@ast

Sildenafil citrate therapy for pulmonary arterial hypertension.

@en

Sildenafil citrate therapy for pulmonary arterial hypertension.

@nl

prefLabel

Sildenafil citrate therapy for pulmonary arterial hypertension.

@ast

Sildenafil citrate therapy for pulmonary arterial hypertension.

@en

Sildenafil citrate therapy for pulmonary arterial hypertension.

@nl

P1433

Q34562650-B7D72710-347A-4FE4-952C-1727B1816C22

P1476

Q34562650-1D048EF8-06F3-4B1B-B016-AC385CC4166B

P2093

Q34562650-3997AD42-7A14-450F-8F60-A61A5F4D9140

Q34562650-3A30E9AC-A512-43DC-954C-A570119DA863

Q34562650-40C2DC9D-015B-4428-85B1-D17C4C272EF1

Q34562650-6DB1C504-BFBD-4F0F-895F-6ED3C63A0125

Q34562650-87A009B5-2CC4-45A2-BB86-4403496EEED2

Q34562650-8F00AA1F-AB52-4F9C-9104-3B63D89309D8

Q34562650-8FE71483-C581-4E17-AA1F-A9C0D5926915

Q34562650-98F9CB98-1B81-4A93-8FA3-182A30B575A6

Q34562650-A5D01F65-BC3A-4720-B2AA-029CDB338A4E

Q34562650-C566BD4B-4F4C-4807-852E-7BED6FC35FFD

P304

Q34562650-18AF826D-3965-4F5C-A994-CF2D4E040EF2

P31

Q34562650-C3848274-8F2B-445D-B20B-496E55AA5859

P356

Q34562650-B59DA3D7-34E2-4759-A3A0-A1512DF43B99

P407

Q34562650-195BED28-8400-46F5-9B4E-027C10C99D74

P433

Q34562650-9FC75A7D-172D-4FEB-9238-6E6AB3E1E578

P478

Q34562650-B146EB5B-8455-4E77-A1F0-02848C254BD3

P50

Q34562650-0B82F886-D26E-4D08-AC86-DC1BA1D0A0C2

P577

Q34562650-840E072D-D14F-4230-AB8A-4BD1A09483A2

P698

Q34562650-B1607B38-15C1-48F2-BF80-FD1E144DC7DA

P356

P1433

The New England Journal of Medicine

P1476

Sildenafil citrate therapy for pulmonary arterial hypertension.

@en

P2093

Adam Torbicki

http://www.w3.org/2001/XMLSchema#string

Angelo Branzi

http://www.w3.org/2001/XMLSchema#string

David Badesch

http://www.w3.org/2001/XMLSchema#string

Gary Burgess

http://www.w3.org/2001/XMLSchema#string

Gérald Simonneau

http://www.w3.org/2001/XMLSchema#string

Hossein A Ghofrani

http://www.w3.org/2001/XMLSchema#string

Lewis J Rubin

http://www.w3.org/2001/XMLSchema#string

Marcin Kurzyna

http://www.w3.org/2001/XMLSchema#string

Nazzareno Galiè

http://www.w3.org/2001/XMLSchema#string

Robyn J Barst

http://www.w3.org/2001/XMLSchema#string

P304

2148-2157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA050010

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

353

http://www.w3.org/2001/XMLSchema#string

P50

Friedrich Grimminger

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16291984

http://www.w3.org/2001/XMLSchema#string